Investigation of miR-144-3p expression levels in HbSS cases with high and normal HbF

AKSOY, Kıymet; ALPARSLAN, Zeliha Nazan; SEYDEL, GONUL SEYDA; GÜZELGÜL, Figen

doi:10.1515/tjb-2019-0496

Investigation of miR-144-3p expression levels in HbSS cases with high and normal HbF

Figen GÜZELGÜL, (Tokat Gaziosmanpaşa Üniversitesi, Eczacılık Fakültesi, Biyokimya Bölümü, Tokat, Türkiye)

Gonul Seyda SEYDE, (Niğde Ömer Halisdemir Üniversitesi, Zübeyde Hanım Sağlık Hizmetleri Meslek Yüksekokulu, Sağlık Hizmetleri Bölümü, Niğde, Türkiye)

Zeliha Nazan ALPARSLAN, (Çukurova Üniversitesi, Tıp Fakültesi, Biyoistatistik Bölümü, Adana, Türkiye)

Kıymet AKSOY (Çukurova Üniversitesi, Tıp Fakültesi, Tıbbi Biyokimya Bölümü, Adana, Türkiye)

Türk Biyokimya Dergisi

7 1

Yıl: 2021 Cilt: 46 Sayı: 1 Sayfa Aralığı: 53 - 58 Metin Dili: İngilizce DOI: 10.1515/tjb-2019-0496 İndeks Tarihi: 21-02-2022

Investigation of miR-144-3p expression levels in HbSS cases with high and normal HbF

Öz:

Background: Sickle cell anemia (HbSS) is a hereditary blood disease that affects millions of people worldwide. Increased the HbF levels affects the clinical course of HbSS positively. The aim of this study was to investigate the association between miR-144-3p and HbSS. Materials and methods: In this study 84 cases (44 HbSS/ HbS combination and 40 HbAA) were performed. The expression of miR-144-3p was determined by RT-PCR. Statistical analysis was performed by the Mann-Whitney U test (SPSS 20.00 for Windows and p<0.005). Results: The miR-144-3p expression levels were higher in the HbSS cases (p≤0.001). Additionally, it was determined that the expression of miR-144-3p was higher in the cases with HbF<3 (p=0.043). Discussion: In our study, the increase in the miR-144-3p levels in low HbF levels may be associated with the severity of the disease. Conclusion: Considering these results, suppressing miR 144-3p may be considered as a new treatment option in HbSS.

Anahtar Kelime:

HbF’i normal ve yüksek olan HbSS’li olgularda miR-144-3p ekspresyon düzeylerinin araştırılması

Öz:

Amaç: Dünya’da milyonlarca insanı etkileyen orak hücreli anemi (Hb SS) bir kalıtsal kan hastalığıdır. Hb F düzeyinin yüksekliği Hb SS’in kliniğini pozitif yönde etkilemektedir. Bu çalışmadaki amacımız miR-144-3p ve HbSS’in birlikte liğini araştırmaktır. Gereç ve Yöntemler: Bu çalışmada 84 olgunun (44 HbSS/ HbS birlikteliği ve 40 HbAA) verileri değerlendirilmiştir. miR-144-3p’nin ekspresyonu RT-PCR ile belirlenmiştir. İstatistiksel analizler Mann-Whitney U testi (Windows SPSS 20.00 ve p<0.005) ile değerlendirilmiştir. Sonuçlar: HbSS olgularında miR-144-3p’nin ekspresyo nunun seviyesi daha yüksek olduğu belirlenmiştir (p ≤ 0.001). Buna ilaveten, Hb F < 3 olan olgularda miR-144- 3p’nin ekspresyon düzeyinin daha yüksek olduğu saptan mıştır (p = 0.043). Tartışma: Çalışmamızda Hb F düzeyi düşük olan olgu larda miR-144-3p ekspresyonunun yüksekliği hastalığın şiddeti ile orantılı olabileceği gözlenmiştir. Sonuç: Bu sonuçlar göz önünde bulundurulduğunda, miR-144-3p ekspresyonunun baskılanması Hb SS’nin tedavisinde yeni bir yaklaşım olabileceği düşünülmüştür.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Koch AA, Yang Q, Olney RS. Sickle hemoglobin (HbS) allele and sickle cell disease: aHuGEreview. Epidemiol 2000;151: 839–45.
2. Stuart M, Nagel R. Sickle cell disease. Lancet 2004;364:1343–60.
3. Akinsheye I, Alsultan A, Solovieff N, Ngo D, Baldwin CT, Sebastiani P, et al. Fetal hemoglobin in sickle cell anemia. Blood 2011;118:19–27.
4. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639–44.
5. Fard AD, Hosseini SA, Shahjahani M, Salari F, Jaseb K. Evaluation of novel fetal hemoglobin inducer drugs in treatment of β-Hemoglobinopathy disorders. Int J Hematol Oncol Stem Cell Res 2013;7:47–54.
6. Grasedieck S, Sorrentino A, Langer C, Buske C, Döhner H, Mertens D, et al. Circulating MicroRNAs in hematological diseases: principles, challenges, and perspectives. Blood 2013;121:4977–84.
7. Ardekani AM, Naeini MM. The role of MicroRNAs in human diseases. Avicenna J Med Biotechnol 2010;2:161–79.
8. Chen SY, Wang Y, Telen MJ, Chi JT. The genomic analysis of erythrocyte MicroRNA expression in sickle cell diseases. PLoS One 2008;3:1–13.
9. Azzouzi I, Moest H, Winkler J, Fauchere JC, Gerber AP, Wollscheid B, et al. MicroRNA-96 directly inhibits γ-globin expression in human erythropoiesis. PLoS One 2011;6:1–11.
10. Yang GH, Wang F, Yu J, Yuan JY, Zhang JW. MicroRNAs are involved in erythroid differentiation control. J Cell Biochem 2009;107:548–56.
11. Budhu A, Ji J, Wang XW. The clinical potential of MicroRNAs. J Hematol Onc 2010;3:1–7.
12. Uwaezuoke N, Emodi I, Ikefuna A, Oguonu T, Okpala I. MicroRNA 221 expression by leukocytes correlates with the clinical severity of sickle cell disease. Haematol Int J 2018;2:000130.
13. Okpala I. The intriguing contribution of white blood cells to sickle cell disease-a red cell disorder. Blood Rev 2004;18:65–73.
14. Roche Diagnositics. Red blood cell lysis buffer; January 2009. Version 7.0.
15. Roche Diagnositics. High pure miRNA isolation kit; 2008. Version 05.3.
16. Exiqon. miRCURY LNATM Universal RT microRNA PCR; 2013. Version 5.3.
17. Guzelgul F, Yalın AE, Aksoy K. The first observation of two alpha globin mutations in Turkey: Hb Stanleyville II and a homozygous 5nt deletion. Turk J Biochem 2014;39:523–8.
18. Ariyurek SY, Yildiz SM, Yalin AE, Guzelgul F, Aksoy K. Hemoglobinopathies in Çukurova region and neighboring provinces. Hemoglobin 2016;40:168–72.
19. Figueiredo MS. The compound state: Hb S/beta-thalassemia. Rev Bras Hematol Hemoter 2015;37:150–2.
20. Cui Lab bioinformatics and systems biology. HMDDV 3.2: The human microRNA disease database version 3.2. https://www. cuilab.cn/hmdd (Last accessed: November 2018).
21. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int J Curr Res Med Sci 2018;4:26–32.
22. Dore LC, Amigo JD, Dos Santos CO, Zhang Z, Gai X, Tobias JW, et al. A GATA-1-regulated microRNA locus essential for erythropoiesis. Proc Natl Acad Sci USA 2008;105:3333–8.
23. Keller A, Leidinger P, Vogel B, Backes C, ElSharawy A, Galata V, et al. miRNAs can be generally associated with human pathologies as exemplified for miR-144. BMC Med 2014;12:224.
24. Ngo DA, Aygun B, Akinsheye I, Hankins JS, Bhan I, Luo HY, et al. Fetal haemoglobin levels and haematological characteristics of compound heterozygous for haemoglobin S and deletional hereditary persistence of fetal haemoglobin. Br J Haematol 2012; 156:259–64.
25. Saki N, Abroun S, Soleimani M, Kavianpour M, Shahjahani M, Mohammadi-Asl J, et al. MicroRNA expression in β-thalassemia and sickle cell disease: a role in the induction of fetal hemoglobin. Cell 2016;17:583–92.
26. Walker AL, Steward S, Howard TA, Mortier N, Smeltzer M, Wang Y-D, et al. Epigenetic and molecular profiles of erythroid cells after hydroxylurea treatment in sickle cell anemia. Blood 2011; 118:5664–70.
27. Fu YF, Du TT, Dong M, Zhu KY, Jing CB, Zhang Y, et al. Mir-144 selectively regulates embryonic alpha-hemoglobin synthesis during primitive erythropoiesis. Blood 2009;113:1340–9.
28. Lawrie CH. MicroRNA expression in erythropoiesis and erythroid disorders. Br J Haematol 2010;150:144–51.
29. Sangokoya C, Telen MJ, Chi JT. MicroRNA miR-144 modulates oxidative stres tolerance and associates with anemia severity in sickle cell disease. Blood 2010;116:4338–48.
30. miRBase. Stem-loop sequence hsa-mir-144. https://www. mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000460 (Last accessed: June 2019).
31. Gene Cards. The human gene database. miR144 Gene (RNA Gene). https://www.genecards.org/cgi-bin/carddisp.pl? gene=MIR144 (Last accessed: June 2019).
32. Li B, Zhu X, Ward CM, Starlard-Davenport A, Takezaki M, Berry A, et al. MIR-144-mediated NRF2 gene silencing inhibits fetal hemoglobin expression in sickle cell disease. Exp Hematol 2019;70:85–96.

APA	GÜZELGÜL F, SEYDEL G, ALPARSLAN Z, AKSOY K (2021). Investigation of miR-144-3p expression levels in HbSS cases with high and normal HbF. , 53 - 58. 10.1515/tjb-2019-0496
Chicago	GÜZELGÜL Figen,SEYDEL GONUL SEYDA,ALPARSLAN Zeliha Nazan,AKSOY Kıymet Investigation of miR-144-3p expression levels in HbSS cases with high and normal HbF. (2021): 53 - 58. 10.1515/tjb-2019-0496
MLA	GÜZELGÜL Figen,SEYDEL GONUL SEYDA,ALPARSLAN Zeliha Nazan,AKSOY Kıymet Investigation of miR-144-3p expression levels in HbSS cases with high and normal HbF. , 2021, ss.53 - 58. 10.1515/tjb-2019-0496
AMA	GÜZELGÜL F,SEYDEL G,ALPARSLAN Z,AKSOY K Investigation of miR-144-3p expression levels in HbSS cases with high and normal HbF. . 2021; 53 - 58. 10.1515/tjb-2019-0496
Vancouver	GÜZELGÜL F,SEYDEL G,ALPARSLAN Z,AKSOY K Investigation of miR-144-3p expression levels in HbSS cases with high and normal HbF. . 2021; 53 - 58. 10.1515/tjb-2019-0496
IEEE	GÜZELGÜL F,SEYDEL G,ALPARSLAN Z,AKSOY K "Investigation of miR-144-3p expression levels in HbSS cases with high and normal HbF." , ss.53 - 58, 2021. 10.1515/tjb-2019-0496
ISNAD	GÜZELGÜL, Figen vd. "Investigation of miR-144-3p expression levels in HbSS cases with high and normal HbF". (2021), 53-58. https://doi.org/10.1515/tjb-2019-0496

APA	GÜZELGÜL F, SEYDEL G, ALPARSLAN Z, AKSOY K (2021). Investigation of miR-144-3p expression levels in HbSS cases with high and normal HbF. Türk Biyokimya Dergisi, 46(1), 53 - 58. 10.1515/tjb-2019-0496
Chicago	GÜZELGÜL Figen,SEYDEL GONUL SEYDA,ALPARSLAN Zeliha Nazan,AKSOY Kıymet Investigation of miR-144-3p expression levels in HbSS cases with high and normal HbF. Türk Biyokimya Dergisi 46, no.1 (2021): 53 - 58. 10.1515/tjb-2019-0496
MLA	GÜZELGÜL Figen,SEYDEL GONUL SEYDA,ALPARSLAN Zeliha Nazan,AKSOY Kıymet Investigation of miR-144-3p expression levels in HbSS cases with high and normal HbF. Türk Biyokimya Dergisi, vol.46, no.1, 2021, ss.53 - 58. 10.1515/tjb-2019-0496
AMA	GÜZELGÜL F,SEYDEL G,ALPARSLAN Z,AKSOY K Investigation of miR-144-3p expression levels in HbSS cases with high and normal HbF. Türk Biyokimya Dergisi. 2021; 46(1): 53 - 58. 10.1515/tjb-2019-0496
Vancouver	GÜZELGÜL F,SEYDEL G,ALPARSLAN Z,AKSOY K Investigation of miR-144-3p expression levels in HbSS cases with high and normal HbF. Türk Biyokimya Dergisi. 2021; 46(1): 53 - 58. 10.1515/tjb-2019-0496
IEEE	GÜZELGÜL F,SEYDEL G,ALPARSLAN Z,AKSOY K "Investigation of miR-144-3p expression levels in HbSS cases with high and normal HbF." Türk Biyokimya Dergisi, 46, ss.53 - 58, 2021. 10.1515/tjb-2019-0496
ISNAD	GÜZELGÜL, Figen vd. "Investigation of miR-144-3p expression levels in HbSS cases with high and normal HbF". Türk Biyokimya Dergisi 46/1 (2021), 53-58. https://doi.org/10.1515/tjb-2019-0496